Amisulpride IV Treatment
Phase 3Small molecule
Amisulpride IV Treatment is one of 41 small molecule programs targeting Nausea and vomiting. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
78 competitors in Nausea and Vomiting
#DrugCompanyPhaseTrials
1Reglan
IIstituto Clinico Humanitas
Approved
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Thalomid
Bristol-Myers SquibbPhase 3
Abraxane
Bristol-Myers SquibbPhase 3
Gemzar
Johnson & JohnsonPhase 3
Megace
Bristol-Myers SquibbPhase 3
Symproic
BBioDelivery Sciences International
Approved
Nereus
VVanda Pharmaceuticals
Phase 3
HSK21542
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Amisulpride IV Treatment
BBenaroya Research Institute
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Nausea and vomiting1 trial
A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea and Vomiting in the Bariatric Surgery Population
Recruiting·—·Phase 3·NCT06585540·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Amisulpride IV Treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- BBenaroya Research Institute